{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:38:29Z","timestamp":1791401909656,"version":"4.3.3"},"reference-count":29,"publisher":"American Society of Hematology","issue":"3","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>B-cell maturation antigen (BCMA)\u2013targeting therapies, including bispecific antibodies (BsAbs) and antibody-drug conjugates (ADCs), are promising treatments for multiple myeloma (MM), but disease may progress after their use. CARTITUDE-2 is a phase 2, multicohort study evaluating the safety and efficacy of cilta-cel, an anti-BCMA chimeric antigen receptor T therapy, in various myeloma patient populations. Patients in cohort C progressed despite treatment with a proteasome inhibitor, immunomodulatory drug, anti-CD38 antibody, and noncellular anti-BCMA immunotherapy. A single cilta-cel infusion was given after lymphodepletion. The primary end point was minimal residual disease (MRD) negativity at 10\u22125. Overall, 20 patients were treated (13 ADC exposed; 7 BsAb exposed; 1 in the ADC group also had prior BsAb exposure). Sixteen (80%) were refractory to prior anti-BCMA therapy. At a median follow-up of 11.3 months (range, 0.6-16.0), 7 of 20 (35%) patients were MRD negative (7 of 10 [70.0%] in the MRD-evaluable subset). Overall response rate (95% confidence interval [CI]) was 60.0% (36.1-80.9). Median duration of response and progression-free survival (95% CI) were 11.5\u00a0(7.9\u2014not estimable) and 9.1 (1.5\u2014not estimable) months, respectively. The most common adverse events were hematologic. Cytokine release syndrome occurred in 12 (60%) patients (all grade 1-2); 4\u00a0had immune effector cell-associated neurotoxicity syndrome (2 had grade 3-4); none had parkinsonism. Seven (35%) patients died (3 of progressive disease, 4 of adverse events [1 treatment related, 3 unrelated]). Cilta-cel induced favorable responses in patients with relapsed\/refractory MM and prior exposure to anti-BCMA treatment who had exhausted other therapies. This trial was registered at www.clinicaltrials.gov as NCT04133636.<\/jats:p>","DOI":"10.1182\/blood.2022015526","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T17:57:54Z","timestamp":1663005474000},"page":"219-230","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":212,"title":["Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents"],"prefix":"10.1182","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-3843","authenticated-orcid":false,"given":"Adam D.","family":"Cohen","sequence":"first","affiliation":[{"name":"1Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"2Hospital Clinico Universitario de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael C.","family":"Cohen","sequence":"additional","affiliation":[{"name":"3Tel-Aviv Sourasky (Ichilov) Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-7785","authenticated-orcid":false,"given":"Paula","family":"Rodriguez-Otero","sequence":"additional","affiliation":[{"name":"4Clinica Universidad de Navarra, CCUN, Centro de Investigaci\u00f3n, Medica Aplicada (CIMA), Instituto de Investigaci\u00f3n, Sanitaria de Navarra (IDISNA, CIBERONC), CIBER-ONC CB16\/12\/00369, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-3815","authenticated-orcid":false,"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[{"name":"4Clinica Universidad de Navarra, CCUN, Centro de Investigaci\u00f3n, Medica Aplicada (CIMA), Instituto de Investigaci\u00f3n, Sanitaria de Navarra (IDISNA, CIBERONC), CIBER-ONC CB16\/12\/00369, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[{"name":"5Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[{"name":"6UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9445-8781","authenticated-orcid":false,"given":"Attaya","family":"Suvannasankha","sequence":"additional","affiliation":[{"name":"7Indiana University Simon Cancer Center, Indiana University and Roudebush VAMC, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7354-1244","authenticated-orcid":false,"given":"Kevin C.","family":"De Braganca","sequence":"additional","affiliation":[{"name":"8Janssen R&D, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Corsale","sequence":"additional","affiliation":[{"name":"8Janssen R&D, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Schecter","sequence":"additional","affiliation":[{"name":"8Janssen R&D, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Varsos","sequence":"additional","affiliation":[{"name":"8Janssen R&D, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1414-2387","authenticated-orcid":false,"given":"William","family":"Deraedt","sequence":"additional","affiliation":[{"name":"9Janssen R&D, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Wang","sequence":"additional","affiliation":[{"name":"8Janssen R&D, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Vogel","sequence":"additional","affiliation":[{"name":"10Janssen Global Services, LLC, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tito","family":"Roccia","sequence":"additional","affiliation":[{"name":"10Janssen Global Services, LLC, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Xu","sequence":"additional","affiliation":[{"name":"8Janssen R&D, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0351-3090","authenticated-orcid":false,"given":"Pankaj","family":"Mistry","sequence":"additional","affiliation":[{"name":"11Janssen R&D, High Wycombe, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Zudaire","sequence":"additional","affiliation":[{"name":"12Janssen R&D, Springhouse, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Akram","sequence":"additional","affiliation":[{"name":"13Legend Biotech USA Inc., Piscataway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonia","family":"Nesheiwat","sequence":"additional","affiliation":[{"name":"13Legend Biotech USA Inc., Piscataway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida","family":"Pacaud","sequence":"additional","affiliation":[{"name":"13Legend Biotech USA Inc., Piscataway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[{"name":"3Tel-Aviv Sourasky (Ichilov) Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jesus","family":"San-Miguel","sequence":"additional","affiliation":[{"name":"4Clinica Universidad de Navarra, CCUN, Centro de Investigaci\u00f3n, Medica Aplicada (CIMA), Instituto de Investigaci\u00f3n, Sanitaria de Navarra (IDISNA, CIBERONC), CIBER-ONC CB16\/12\/00369, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2023082419145182600_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"suppl 2","key":"2023082419145182600_bib2","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.21037\/atm.2018.11.14","article-title":"BCMA CAR T-cell therapy arrives for multiple myeloma: a reality","volume":"6","author":"Cho","year":"2018","journal-title":"Ann Transl Med"},{"key":"2023082419145182600_bib3","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"key":"2023082419145182600_bib4","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fimmu.2020.00501","article-title":"Bispecific antibodies for multiple myeloma: a review of targets, drugs, clinical trials, and future directions","volume":"11","author":"Caraccio","year":"2020","journal-title":"Front Immunol"},{"issue":"7","key":"2023082419145182600_bib5","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/14712598.2020.1802422","article-title":"Antibody-drug conjugates for multiple myeloma","volume":"21","author":"McMillan","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"suppl 1","key":"2023082419145182600_bib6","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2021-150519","article-title":"Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from Magnetism-1 [abstract]","volume":"138","author":"Sebag","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023082419145182600_bib7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2021-147915","article-title":"Updated results from MajesTEC-1: Phase 1\/2 study of teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in relapsed\/refractory multiple myeloma [abstract]","volume":"138","author":"Moreau","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023082419145182600_bib8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2021-144921","article-title":"Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a\u00a0BCMAxCD3 bispecific monoclonal antibody, in a phase 1\/2 first-in-human study in patients with relapsed\/refractory multiple myeloma (RRMM) [abstract]","volume":"138","author":"Zonder","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2023082419145182600_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J"},{"issue":"15_suppl","key":"2023082419145182600_bib10","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/JCO.2019.37.15_suppl.8007","article-title":"Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R\/R multiple myeloma (MM) patients: updated results of a first-in-human (FIH) phase I dose escalation study","volume":"37","author":"Topp","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2023082419145182600_bib11","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2021-150757","article-title":"A\u00a0phase 1 first-in-human study of Tnb-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in\u00a0patients with relapsed\/refractory multiple\u00a0myeloma [abstract]","volume":"138","author":"Kumar","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023082419145182600_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2019-122895","article-title":"First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial [abstract]","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"issue":"10297","key":"2023082419145182600_bib13","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study [abstract]","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"2023082419145182600_bib14","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2 years follow-up","author":"Martin","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2023082419145182600_bib15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"2023082419145182600_bib16","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1182\/bloodadvances.2019000466","article-title":"Serial treatment of relapsed\/refractory multiple myeloma with different BCMA-targeting therapies","volume":"3","author":"Cohen","year":"2019","journal-title":"Blood Adv"},{"issue":"18","key":"2023082419145182600_bib17","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2023082419145182600_bib18","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"2023082419145182600_bib19","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/leu.2015.290","article-title":"Clarification of the definition of complete response in multiple myeloma","volume":"29","author":"Durie","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"2023082419145182600_bib20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"2023082419145182600_bib21","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2023082419145182600_bib22","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2023082419145182600_bib23","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1182\/blood-2021-150998","article-title":"Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment [abstract]","volume":"138","author":"Baljevic","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023082419145182600_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study [abstract]","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023082419145182600_bib25","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1182\/blood-2021-147704","article-title":"Iberdomide (IBER) in combination with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the dose-expansion phase of the CC-220-MM-001 trial [abstract]","volume":"138","author":"Lonial","year":"2021","journal-title":"Blood"},{"issue":"15_suppl","key":"2023082419145182600_bib26","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2021.39.15_suppl.8006","article-title":"Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023082419145182600_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"2023082419145182600_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"8","key":"2023082419145182600_bib29","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","article-title":"Risk of infections with B cell maturation antigen (BCMA) directed immunotherapy in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/3\/219\/2073559\/blood_bld-2022-015526-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/3\/219\/2073559\/blood_bld-2022-015526-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T15:17:08Z","timestamp":1692890228000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/3\/219\/486575\/Efficacy-and-safety-of-cilta-cel-in-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,1,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022015526","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742319499.793596099","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]}}}